AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25730290
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTX‐A) - single dose of 10 units per kilogram body weight
Trial: 22591059
Drug: Step-up treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up treatment strategy (antacid 4dd + placebo 1dd)
Trial: 22591059
Drug: Step-down treatment
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down treatment strategy (proton pump inhibitor 1dd + placebo 4dd)
Trial: 22591059
Drug: Step 3
RxNorm normalized name: Nicotine Patch Step 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 3 (five pills/day, placebo and verum vice versa from step 1)
Trial: 22591059
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication vs. placebo
Trial: 18950330
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (2 mcg x kg(‐1)) and infraorbital nerve block with 0.5 ml preservative-free normal saline on each side
Trial: 18950330
Drug: Bilateral infraorbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral infraorbital nerve blocks with 0.5 ml on each side of 0.25% bupivacaine and 2 ml of preservative-free saline solution intravenously
Trial: 16192766
Drug: Rapid crystalloid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid crystalloid infusion (group 1)
Trial: 16192766
Drug: Minimal maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal maintenance rate crystalloid infusion (group 0)
Trial: 10385641
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) treatment for 4 weeks
Trial: 1802393
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg NGT
Trial: 6828256
Drug: Aqueous suspension
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous suspension of cofosfolactamines
Trial: 6828256
Drug: Tablets of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of cofosfolactamines
Trial: 29850450
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil group (receiving 20% of total daily energy from olive oil)
Trial: 27267431
Drug: Lispro administered
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lispro administered by QS-M needle-free jet injector
Trial: 24598007
Drug: Ciclesonide nasal
RxNorm normalized name: ciclesonide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide nasal aerosol (CIC-HFA) 74-μg (37 μg/spray, 1 spray/each nostril)
Trial: 24598007
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate monohydrate aqueous nasal spray (MFNS) 200-μg (50 μg/spray, 2 sprays/each nostril)
Trial: 22374626
Drug: Cognitive restructuring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive restructuring (cognitive therapy)
Trial: 22374626
Drug: Systematic desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systematic desensitization (behavioral therapy)
Trial: 18323413
Drug: Testosterone and
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone and sex hormone binding globulin
Trial: 11818522
Drug: Low fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fatty acid amide hydrolase (FAAH) activity in lymphocytes of IVF-embryo transfer patients who failed to achieve an ongoing pregnancy (46 +/- 17 pmol/min per mg protein)
Trial: 11818522
Drug: Increased blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased blood anandamide (AEA) levels in patients who failed to achieve an ongoing pregnancy (4.0 +/- 2.2 pmol/ml)
Trial: 11818522
Drug: No difference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No difference in the activity of the AEA membrane transporter or amounts of cannabinoid receptors in lymphocytes between groups
Trial: 26204331
Drug: Low-dose olprinone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose olprinone continuously infused for 24 hours starting just before anesthesia induction
Trial: 26204331
Drug: Low-dose olprinone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose olprinone
Trial: 23709289
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (3 mg/kg) before passive heat loading (PHL)
Trial: 24683674
Drug: Daily Sprinkles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Sprinkles (12.5 mg of elemental iron, n = 79)
Trial: 24683674
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly Sprinkles (30 mg of elemental iron, n = 73)
Trial: 15342807
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human leptin treatment for up to three months
Trial: 15342807
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human leptin treatment
Trial: 1338742
Drug: Live enterovirus
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live enterovirus oral vaccines, administered in 2-3 doses at intervals of 7-10 days.
Trial: 4014743
Drug: 2 or
RxNorm normalized name: CP-2 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or more mg of morphine
Trial: 4014743
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg morphine (control)
Trial: 4014743
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg morphine
Trial: 31199765
Drug: Fresh coconut
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Fresh Coconut Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh coconut (100 g daily)
Trial: 26865472
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal delivery system (BTDS) 5 mg
Trial: 26865472
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal delivery system (BTDS) 10 mg
Trial: 26865472
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal delivery system (BTDS) 20 mg
Trial: 26865472
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine infusion
Trial: 24828298
Drug: PUVAsol +
RxNorm normalized name: docusate sodium / sennosides, USP Oral Tablet [Purgasol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVAsol + isotretinoin (0.5 mg/kg/day)
Trial: 15921865
Drug: Conjugated estrogens/medroxyprogesterone
RxNorm normalized name: Conjugated Estrogens/Medroxyprogesterone Acetate 0.625 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.625/2.5 mg daily for 24 weeks
Trial: 15921865
Drug: Conjugated estrogens/medroxyprogesterone
RxNorm normalized name: Conjugated Estrogens/Medroxyprogesterone Acetate 0.625 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.45/1.5 mg daily for 24 weeks
Trial: 15921865
Drug: Conjugated estrogens/medroxyprogesterone
RxNorm normalized name: Conjugated Estrogens/Medroxyprogesterone Acetate 0.625 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.3/1.5 mg daily for 24 weeks
Trial: 11938636
Drug: Southern Implants
RxNorm normalized name: Fluzone 2025 Southern Hemisphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Southern Implants (test group)
Trial: 11938636
Drug: Southern Implants
RxNorm normalized name: Fluzone 2025 Southern Hemisphere
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Southern Implants (control group)
Trial: 10190531
Drug: Nicorandil therapy
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil therapy for 2 weeks
Trial: 2253292
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 10-15 micrograms.kg-1 (Group I)
Trial: 2253292
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1 (Group II)
Trial: 30993861
Drug: metformin 1000-1500
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 1000-1500 mg daily
Trial: 25588587
Drug: Intravenous high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high single-dose of iron isomaltoside 1000 (1,200 mg)
Trial: 24114290
Drug: 0.25% topical
RxNorm normalized name: Remyda, 0.25% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% topical sodium lauryl sulfate (SLS)
Trial: 24114290
Drug: 0.5% topical
RxNorm normalized name: Carac 0.5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% topical sodium lauryl sulfate (SLS)
Trial: 24114290
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical sodium lauryl sulfate (SLS)
Trial: 24114290
Drug: 2% topical
RxNorm normalized name: A/T/S 2% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% topical sodium lauryl sulfate (SLS)
Trial: 19132712
Drug: Aripiprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (10 mg/day for 3 days, 20 mg/day for 3 days, then 30 mg/day for 8 days)
Trial: 15220020
Drug: Oxycodone/acetaminophen 5/325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/acetaminophen 5/325 mg
Trial: 11521984
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg bid for 4 weeks
Trial: 2842206
Drug: nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nedocromil sodium (4 mg twice daily)
Trial: 31712421
Drug: suvorexant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suvorexant (20 mg)
Trial: 31712421
Drug: brotizolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brotizolam (0.25 mg)
Trial: 23337558
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy (6 treatments over 4 weeks)
Trial: 23337558
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (answered HIT-6 questionnaire twice before receiving treatment)
Trial: 21622496
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (measured in UK units, 8 g of ethanol) in quitters
Trial: 21622496
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (measured in UK units, 8 g of ethanol) in smokers
Trial: 17116022
Drug: RWJ-333369 alone
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-333369 alone (5 days 250 mg q12h; 5 days 500 mg q12h)
Trial: 17116022
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) alone (3 days 100 mg q12h; 3 days 200 mg q12h; 22 days 300 mg q12h)
Trial: 17116022
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBZ (300 mg q12h) and RWJ-333369 (5 days 250 mg q12h; 5 days 500 mg q12h)
Trial: 9255651
Drug: Intermittent furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent furosemide administration
Trial: 9255651
Drug: Continuous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous furosemide infusion
Trial: 28848766
Drug: Intelligent Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year
Trial: 28848766
Drug: Intelligent Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intelligent Physical Exercise Training (IPET) for 1 hour weekly for 1 year with adherence ≥70%
Trial: 26481739
Drug: Intravaginal 25-μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 25-μg misoprostol
Trial: 23880883
Drug: Tio plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tio plus SFC (18 μg once daily + 50/250 μg twice daily)
Trial: 23880883
Drug: Tio (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tio (18 μg once daily)
Trial: 23880883
Drug: SM (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM (50 μg twice daily)
Trial: 23880883
Drug: SFC (50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (50/250 μg twice daily)
Trial: 17522609
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (50 mg/day)
Trial: 17522609
Drug: Combined iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined iron and zinc supplementation (50 mg/day iron and 14 mg/day zinc)
Trial: 17522609
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (14 mg/day)
Trial: 12684151
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (400 micro g)
Trial: 15070888
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (400 micro g)
Trial: 11254789
Drug: Naltrexone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (5 mg/kg/day)
Trial: 8508009
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder (daily dose, 800 mg)
Trial: 30021690
Drug: Orlistat 48-mg
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 48-mg tablet
Trial: 30021690
Drug: Orlistat 144-mg
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 144-mg tablet
Trial: 30021690
Drug: Orlistat 24-mg
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 24-mg tablet
Trial: 24728578
Drug: CP-CEF (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-CEF (carboplatin and weekly paclitaxel followed by CEF)
Trial: 24728578
Drug: P-CEF (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-CEF (weekly paclitaxel followed by CEF)
Trial: 22242619
Drug: Mentoring in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentoring in addition to treatment
Trial: 22242619
Drug: More mentoring
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More mentoring with fewer treatment sessions
Trial: 15701489
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine (EBM) group (1-hour EBM journal club)
Trial: 11340102
Drug: Garlic oil
RxNorm normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic oil (GO) 8.2 mg/d (allyl sulfides) for 11 weeks
Trial: 11340102
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder (GP) 7.8 mg allicin/d for 11 weeks
Trial: 2481163
Drug: Nifedipine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (in patients already on a beta-blocker)
Trial: 27237598
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patches (TNP)
Trial: 23757426
Drug: Insulin-sensitizing (IS)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-sensitizing (IS) strategy
Trial: 23757426
Drug: Insulin-providing (IP)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-providing (IP) strategy
Trial: 23757426
Drug: Insulin-sensitizing (IS)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-sensitizing (IS) strategy in men
Trial: 15331896
Drug: Switching drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching drugs after no improvement
Trial: 11422094
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg acetylsalicyclic acid (ASA)
Trial: 8125421
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous streptokinase)
Trial: 8125421
Drug: Captopril 3
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril 3 mg
Trial: 8125421
Drug: Captopril (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (doses not specified)
Trial: 3337794
Drug: Morphine 100
RxNorm normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 100 micrograms kg‐1
Trial: 3337794
Drug: Morphine 50
RxNorm normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 50 micrograms kg‐1
Trial: 3337794
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and Buprenorphine (both dosages)
Trial: 3337794
Drug: Buprenorphine and
RxNorm normalized name: Buprenorphine and Naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine and Morphine
Trial: 26938860
Drug: Isotretinoin treatment
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin treatment for acne vulgaris for 6 months
Trial: 24256373
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no isotretinoin treatment)
Trial: 23848184
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g intravenous albumin for the first 3 days within the first week of ICU stay (group A)
Trial: 23848184
Drug: No albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No albumin treatment (group B)
Trial: 21942435
Drug: High-dose hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hydrocortisone (0.45 mg/kg IV)
Trial: 21942435
Drug: Moderate-dose hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moderate-dose hydrocortisone (0.15 mg/kg IV)
Trial: 18450517
Drug: Tarenflurbil 800
RxNorm normalized name: Tarenflurbil
DrugBank: Tarenflurbil (DB05289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarenflurbil 800 mg twice per day
Trial: 18450517
Drug: Tarenflurbil 800
RxNorm normalized name: Tarenflurbil
DrugBank: Tarenflurbil (DB05289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarenflurbil 800 mg twice per day for 24 months
Trial: 15829988
Drug: Vardenafil (PDE-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (PDE-5 inhibitor)
Trial: 12873331
Drug: Clonazepam maintenance
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonazepam maintenance treatment (CMT)
Trial: 8595686
Drug: Thiopentone 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 2.5% (50 mg)
Trial: 1207275
Drug: Arginine infusion
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine infusion of 0.5 g/kg over 30 minutes